載入中
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
收盤時
US$21.56
−US$2.88 · -11.78%
盤後
US$21.56
US$0.00 · 0.00%
10月13日 下午4:27 ET
盤中時間採用ET。市場資料可能有所延遲。
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
日內區間
目前US$21.56
52週區間
目前US$21.56
盤中時間採用ET。市場資料可能有所延遲。
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
日內區間
目前US$21.56
52週區間
目前US$21.56
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 92.5萬 USD | — | — | — |
| 銷貨成本 | 319.2萬 USD | 324.7萬 USD | 326.2萬 USD | 319.6萬 USD | 4226.4萬 USD |
| 毛利 | −319.2萬 USD | −232.2萬 USD | −326.2萬 USD | −319.6萬 USD | −4226.4萬 USD |
| 研究與開發 | 7501.1萬 USD | 6091.7萬 USD | 4439.4萬 USD | 4750.5萬 USD | 4226.4萬 USD |
| 銷售、一般及管理費用 | 2512.5萬 USD | 2261.3萬 USD | 1118.9萬 USD | 901.2萬 USD | 827萬 USD |
| 營業費用 | 1億 USD | 8028.3萬 USD | 5232.1萬 USD | 5332.1萬 USD | 827萬 USD |
| 利息收入 | 1154.7萬 USD | 846.7萬 USD | 295.1萬 USD | 133.7萬 USD | 1.9萬 USD |
| 利息支出 | 5000 USD | 1.2萬 USD | 1.2萬 USD | 2000 USD | — |
| 折舊和攤銷 | 309.2萬 USD | 324.7萬 USD | 329.7萬 USD | 320萬 USD | 94.7萬 USD |
| 營業利益 | −1.03億 USD | −8260.5萬 USD | −5558.3萬 USD | −5651.7萬 USD | −5053.4萬 USD |
| 淨利 | −9035.1萬 USD | −7514.4萬 USD | −3631.7萬 USD | −5518.9萬 USD | −5051.7萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年12月19日 | 1:4 | — | — |
股票分割 | 2023年9月25日 | 1:5 | — | — |
已生效 2023年12月19日
1:4
已生效 2023年9月25日
1:5
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM976.86萬0.01%787.4億 USD0.19%US$276.71-0.43%
State Street SPDR S&P Biotech ETFXBI680.7萬0.07%103.03億 USD0.35%US$146.8-3.04%
iShares Russell 2000 Value ETFIWN354.98萬0.03%137.49億 USD0.24%US$210.99-0.05%
iShares Biotechnology ETFIBB303.68萬0.03%108.2億 USD0.44%US$200.02-2.08%
Fidelity Enhanced Small Cap ETFFESM267.98萬0.04%64.1億 USD0.28%US$45.15-0.20%
Vanguard Russell 2000 ETFVTWO235.71萬0.01%180億 USD0.06%US$111.77-0.45%
iShares Micro-Cap ETFIWC121.49萬0.09%13.17億 USD0.60%US$179.6-1.13%
Vanguard Health Care ETFVHT114.28萬0.01%220億 USD0.09%US$316.37-1.34%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
